Table 2.
FPV concentration, µg/mL | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | Day 8 | Day 9 | Day 10 | |||||||||||
1,600 mg | 1,600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | 600 mg | |
Patient 1 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | 2.7 | NA | NA | NA | ||||||||||
(8 hours) | (11 hours) | (11 hours) | (12 hours) | (10 hours) | (11 hours) | (10 hours) | ||||||||||||||
Patient 2 | 2.5 | 1.2 | < 1.0 | < 1.0 | < 1.0 | NA | NA | NA | NA | NA | ||||||||||
(8 hours) | (12 hours) | (11 hours) | (11 hours) | (9 hours) | ||||||||||||||||
Patient 3 | 3.9 | 5.5 | 1.7 | 2.4 | 3 | NA | NA | NA | NA | NA | ||||||||||
(10 hours) | (12 hours) | (11 hours) | (10 hours) | (9 hours) | ||||||||||||||||
Patient 4 a | 45.6, 38.8, 34.0 | 17.4, 16.8 | 8.8 | 5.3 | 2.4 | NA | NA | NA | NA | NA | ||||||||||
(8, 9, 10 hours) | (10, 10.3 hours) | (13 hours) | (9 hours) | (11 hours) | ||||||||||||||||
Patient 5 a | 41.6 | 25.8 | 5.6 | < 1.0 | 2.8, < 1.0 | < 1.0 | NA | NA | NA | NA | NA | |||||||||
(6 hours) | (6 hours) | (11 hours) | (11 hours) | (5, 11 hours) | (10 hours) | |||||||||||||||
Patient 6 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | < 1.0 | ||||||||||
(12 hours) | (11 hours) | (11 hours) | (11 hours) | (11 hours) | (11 hours) | (12 hours) | (10 hours) | (12 hours) | (12 hours) | |||||||||||
Patient 7 | < 1.0 | 23 | 3 | < 1.0 | < 1.0, < 1.0 | < 1.0 | NA | NA | NA | NA | NA | |||||||||
(1 hours) | (9 hours) | (12 hours) | (10 hours) | (10, 12 hours) | (11 hours) |
() indicates blood sampling time after administration.
COVID‐19, coronavirus disease 2019; FPV, favipiravir; NA, not applicable.
FPV (1,600 mg) was taken twice orally on day 1.